Remove Drugs Remove In-Vitro Remove Medicine
article thumbnail

Vertex gains FDA approval for expanded use of CF drug Trikafta

Pharmaceutical Technology

Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) to expand the use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to treat cystic fibrosis (CF) in children aged between two and five years with certain mutations.

article thumbnail

Vertex secures FDA clearance for infants’ cystic fibrosis therapy

Pharmaceutical Technology

Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for KALYDECO (ivacaftor) to treat children with cystic fibrosis (CF) aged between one and four months. The medicine is currently available for use in more than 30 countries.

In-Vitro 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

General Design Methods for mRNA Drugs

Pharma Mirror

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130
article thumbnail

China’s NMPA clears Transcenta’s IND for solid tumour treatment

Pharmaceutical Technology

The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted clearance for Transcenta’s investigational new drug (IND) application for its TST003 to treat solid tumours. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.

Antibody 242
article thumbnail

Promising results from in vitro combination therapy against COVID-19

Scienmag

Researchers at Karolinska Institutet in Sweden report promising results from an in vitro combination therapy against COVID-19. Credit: Martin Stenmark.

article thumbnail

UTHSC researchers identify three drugs as possible therapeutics for COVID-19

Scienmag

(November 18, 2020)–Researchers at the University of Tennessee Health Science Center working with colleagues at the University of New Mexico have identified three drugs, already approved for other uses in humans, as possible therapeutics for COVID-19, the illness caused by the SARS-CoV-2 virus.

article thumbnail

Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety

pharmaphorum

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98